RxDoctor Payments Data

Kourtney Harrington, MD

Internal Medicine · Bella Vista, ARNPI 1962762682

Payments from drug & device makers

$3,070in general payments, 2019–2025

Across 202 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$531
  • GSK$445
  • AbbVie$431
  • Pfizer$349
  • Astellas Pharma US Inc$279
  • Novo Nordisk$202
  • plus $833 from 19 others

What the payments were for

  • Food & beverage$3,070100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,070 in reported general payments places this provider in the 80th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$235,484
Medicare patients
333
Services billed
8,295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$79,562
OzempicSemaglutide62$73,888
MounjaroTirzepatide55$68,451
JardianceEmpagliflozin50$51,771
ProliaDenosumab29$50,434
Repatha SureclickEvolocumab57$35,915
FarxigaDapagliflozin Propanediol37$27,842
TrulicityDulaglutide14$22,327
MyrbetriqMirabegron34$21,779
RybelsusSemaglutide15$21,502
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$21,191
XareltoRivaroxaban23$15,814
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$11,838
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$8,796
LinzessLinaclotide15$8,105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$202$95,39077 claims
Lilly USA, LLCMounjaro, Trulicity$87$90,77869 claims
PfizerEliquis$349$79,56299 claims
Boehringer IngelheimJardiance$64$51,77150 claims
AmgenProlia$531$50,43429 claims
GSKTrelegy Ellipta, Anoro Ellipta$445$33,02946 claims
AstraZenecaFarxiga, Symbicort$75$32,65049 claims
Astellas Pharma US IncMyrbetriq$279$21,77934 claims
Johnson & JohnsonXarelto$111$15,81423 claims
MerckBelsomra, Januvia$29$14,49829 claims
AbbVieLinzess, Synthroid$431$11,06959 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Bella Vista

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →